When people search for a Hims weight loss alternative, they are usually not looking to be told that one platform is objectively better than another. They are trying to figure out whether there is a program that fits their specific situation better than what Hims offers. That is a fair question, and it deserves a fair answer.

This article is published by EllieMD, so you should factor that into how you read it. We have tried to represent Hims' actual program accurately and to be honest about where each platform has genuine strengths. The goal is to help you figure out which one makes sense for you, not to dismiss a legitimate competitor.

Hims and Hers is a publicly traded telehealth company with roughly $2.35 billion in 2025 revenue and one of the highest brand recognition profiles in the direct-to-consumer health space. Its GLP-1 program uses compounded semaglutide, includes a physician consultation process, and delivers medication by mail.

Hims' core strengths are scale, brand recognition, and operational efficiency. The platform processes a large volume of patients and has invested significantly in product design and user experience. Its pricing for compounded semaglutide has been competitive within the market, and its broad brand awareness means many people encounter it first in their research.

Where Hims is primarily structured as a transactional platform. You consult, subscribe, receive medication, and manage your experience largely independently. Physician access beyond the initial consultation and prescription renewal is limited compared to platforms built specifically around ongoing clinical engagement.

EllieMD was built around a specific premise: that GLP-1 outcomes improve substantially when patients have physician oversight, community accountability, and structured support alongside their prescription. This is not a marketing claim. It is grounded in research.

A study from Northwestern University found that community-supported weight loss programs produced outcomes approximately double those of individually managed approaches. The mechanism is straightforward. Weight loss is hard, adherence is the most common point of failure, and accountability through community significantly improves adherence. You can read more in our community support article.

EllieMD's weight loss program integrates physician oversight throughout treatment, not just at the beginning. If you hit a rough patch with side effects, if your progress stalls, or if you want to discuss adjusting your protocol, your care team is accessible. This ongoing relationship is a structural feature of how the program is designed, not an upsell.

The medication formulation is also different. EllieMD uses compounded semaglutide combined with L-carnitine, which supports fatty acid oxidation alongside the appetite-regulating effects of GLP-1 therapy. Hims uses semaglutide alone. Whether the combination matters for your specific goals is a conversation worth having with a physician.

EllieMD also offers a dedicated microdosing program for patients who want a more gradual, lower-dose approach. This is not something Hims structures as a distinct offering.

If you are doing this research because you tried a GLP-1 program before and did not stick with it, the community piece is probably the most relevant differentiator to think about.

The number one reason people do not achieve their GLP-1 potential is not that the medication does not work. It is that they stop the medication or disengage from the program. Side effects, motivation that fades after the initial excitement, lack of accountability, and the absence of social reference points all contribute.

EllieMD's community gives you access to people who are at the same stage you are, people who have pushed through the side effect window you are in, people who have hit the plateau you are facing. That shared experience is not replicable by a one-to-one clinical relationship alone. It is also not something a transactional subscription platform provides.

Over 200,000 people are working through health goals on EllieMD's platform. That scale creates a community with real density at every stage of the journey. Learn more about the thinking behind the model at /our-story.

Being honest here: Hims is a better fit for some people than EllieMD.

If you are highly self-directed, confident you will stay adherent without community support, and primarily looking for the lowest-friction path to a GLP-1 prescription, Hims is a legitimate option. The brand is established, the operational infrastructure is solid, and the medication is the same active compound.

If you have significant brand sensitivity and feel more comfortable with a well-recognized name, Hims has a meaningful advantage there.

If you want broad-platform health services beyond weight loss, including sexual health, mental health, and hair loss in one subscription, Hims' range may suit your needs better than EllieMD's more focused scope.

If you have tried GLP-1 therapy or another weight loss program before and struggled with adherence, EllieMD's accountability structure directly addresses the most common failure point.

If you want ongoing physician access beyond the initial consultation, rather than a primarily self-managed experience, EllieMD's care model is designed around that.

If you want a formulation that goes beyond semaglutide alone, or if you want the option of a microdosing approach, EllieMD has both.

If the community model resonates with you because you know yourself well enough to know that isolation tends to derail your consistency, EllieMD was built for exactly that situation.


Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.